Gallus Biopharmaceuticals has acquired Johnson & Johnson's Centocor biologics campus in St Lousis, MO, following an equity investment by Ridgemont Equity Partners. Ridgemont has taken a majority stake in Gallus. Gallus will retain 160 jobs at the facility and plans to expand the facility’s manufacturing capabilities, including building a clinical services suite and expanding the existing development lab, and add 160 further jobs over the next five years.
Ridgemont
St Louis Today
Thursday 19 May 2011
Gallus acquires site, plans expansion
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment